Business Context and Reporting Period
Company: Modular Medical, Inc. (MODD)
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Three and six months ended September 30, 2025
Business Overview: Modular Medical is a pre-revenue medical device company developing innovative insulin delivery systems. The company received FDA clearance for its initial product, MODD1, in September 2024 and announced the first human use in August 2025. It is currently seeking FDA approval for its next-generation "Pivot" patch pump, with a 510(k) submission expected in Q1 2026.
Key Financial Metrics
| Metric (in thousands) | Six Months Ended Sept 30, 2025 | Six Months Ended Sept 30, 2024 |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(14,492) | $(9,093) |
| Operating Expenses | $14,633 | $9,216 |
| Cash and Cash Equivalents (Sept 30, 2025) | $5,316 | $3,893 (Sept 30, 2024) |
| Accumulated Deficit | $(99,245) | $(75,022) |
| Net Cash Used in Operating Activities | $(10,783) | $(7,314) |
| Net Cash Provided by Financing Activities | $4,709 | $2,978 |
Material Changes vs. Prior Period
- Increased Operating Costs: Total operating expenses rose 58.8% to $14.6 million for the six months ended September 30, 2025, compared to $9.2 million in the prior year period.
- R&D Expenses: Increased 55.3% to $10.7 million, driven by higher personnel costs ($1.9M increase), materials, and consulting fees. R&D headcount grew from 42 to 56 employees.
- SG&A Expenses: Increased 69.2% to $3.9 million, primarily due to expanded personnel ($0.8M increase) and marketing efforts. SG&A headcount grew from 4 to 13 employees.
- Capital Expenditures: Cash used in investing activities increased to $1.7 million (from $1.0 million) due to purchases of property and equipment for manufacturing capabilities.
- Financing Activity: The company raised approximately $3.9 million in net proceeds from a warrant inducement offering in September 2025 and $0.7 million from at-the-market (ATM) sales during the six-month period.
Outlook, Risks, and Management Commentary
- Going Concern Warning: Management and the independent auditor have expressed substantial doubt about the company's ability to continue as a going concern for at least one year from the filing date. The company has no revenue and relies on raising additional capital to fund operations.
- Product Timeline: The company expects to initiate commercial launch of the "Pivot" product in the first half of calendar year 2026, pending FDA approval. R&D and SG&A expenses are expected to increase in the second half of fiscal 2026 to support commercialization.
- Nasdaq Compliance: The company received notice from Nasdaq on June 30, 2025, that it failed to meet the minimum bid price requirement of $1.00 per share. It has 180 days (until December 29, 2025) to regain compliance or risk delisting.
- Subsequent Events: Following the period end, the company sold approximately 1.8 million shares under its ATM program for net proceeds of $1.1 million.
Investor Verification Checklist
- Liquidity Runway: Verify if the $5.3 million cash balance (plus subsequent $1.1M ATM proceeds) is sufficient to fund operations through the expected Q1 2026 commercial launch of the Pivot product.
- Regulatory Status: Confirm the status of the 510(k) submission for the "Pivot" product and the timeline for FDA clearance.
- Nasdaq Compliance: Monitor the stock price to ensure it meets the $1.00 minimum bid price requirement for 10 consecutive days before the December 29, 2025 deadline to avoid delisting.
- Capital Requirements: Assess the company's ability to secure further equity or debt financing given the substantial accumulated deficit of $99.2 million and ongoing cash burn.
- Manufacturing Capacity: Verify progress on the validation of the manufacturing line for the Pivot pump, a key milestone for expense recognition and commercial readiness.